Unicycive Therapeutics, Inc. (UNCY)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Shalabh K. Gupta M.D., MPA
|
Founder, Chairman, CEO & President | 1.06M | -- | 1973 |
|
Dr. Pramod Gupta Ph.D.
|
Executive Vice President of Pharmaceutical and Business Operations | 666.9k | -- | 1960 |
|
Mr. Douglas Jermasek M.B.A.
|
Executive Vice President of Corporate Strategy | 440.14k | -- | 1961 |
|
Mr. John W. Townsend CPA
|
Chief Financial Officer | 197.86k | -- | 1962 |
Unicycive Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 21
Description
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Corporate Governance
Upcoming Events
November 12, 2026 at 1:30 PM UTC
Unicycive Therapeutics, Inc. Earnings Date
Recent Events
June 11, 2026 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
